WO2011057580A1 - 有机二羧酸和其盐及其制备方法 - Google Patents
有机二羧酸和其盐及其制备方法 Download PDFInfo
- Publication number
- WO2011057580A1 WO2011057580A1 PCT/CN2010/078691 CN2010078691W WO2011057580A1 WO 2011057580 A1 WO2011057580 A1 WO 2011057580A1 CN 2010078691 W CN2010078691 W CN 2010078691W WO 2011057580 A1 WO2011057580 A1 WO 2011057580A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lysine
- histidine
- benzyl
- dicarboxylic acid
- group
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 25
- 150000001991 dicarboxylic acids Chemical class 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 50
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 35
- 239000004472 Lysine Substances 0.000 claims description 32
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 29
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 29
- 235000018977 lysine Nutrition 0.000 claims description 29
- 229960002885 histidine Drugs 0.000 claims description 25
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 20
- -1 dicarboxylic acid group compound Chemical class 0.000 claims description 11
- 229940024606 amino acid Drugs 0.000 claims description 9
- 235000001014 amino acid Nutrition 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims description 5
- 229930195721 D-histidine Natural products 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 235000019766 L-Lysine Nutrition 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 150000001768 cations Chemical class 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical group CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000002346 iodo group Chemical group I* 0.000 claims description 2
- 125000001142 dicarboxylic acid group Chemical group 0.000 claims 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 claims 1
- 229930004069 diterpene Natural products 0.000 claims 1
- 150000004141 diterpene derivatives Chemical class 0.000 claims 1
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 1
- 210000001508 eye Anatomy 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 230000006378 damage Effects 0.000 abstract description 2
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 abstract 2
- 210000000695 crystalline len Anatomy 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 30
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 28
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 24
- 230000004792 oxidative damage Effects 0.000 description 11
- 208000002177 Cataract Diseases 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- IGULOYSOGFNAFG-UHFFFAOYSA-N 2-(1-benzylindazol-3-yl)oxypropanedioic acid Chemical compound C12=CC=CC=C2C(OC(C(=O)O)C(O)=O)=NN1CC1=CC=CC=C1 IGULOYSOGFNAFG-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical group OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical class NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000001437 anti-cataract Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940073608 benzyl chloride Drugs 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical class [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 2
- HCDITHVDEPPNIL-UHFFFAOYSA-L dipotassium;propanedioate Chemical compound [K+].[K+].[O-]C(=O)CC([O-])=O HCDITHVDEPPNIL-UHFFFAOYSA-L 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 0 **1C=CC(C[n](c2ccccc22)nc2OCC(O)=O)=CC=C1 Chemical compound **1C=CC(C[n](c2ccccc22)nc2OCC(O)=O)=CC=C1 0.000 description 1
- SWEICGMKXPNXNU-UHFFFAOYSA-N 1,2-dihydroindazol-3-one Chemical compound C1=CC=C2C(O)=NNC2=C1 SWEICGMKXPNXNU-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 229940118148 Aldose reductase inhibitor Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical compound CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010024214 Lenticular opacities Diseases 0.000 description 1
- 230000010718 Oxidation Activity Effects 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 150000005524 benzylchlorides Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- FNJVDWXUKLTFFL-UHFFFAOYSA-N diethyl 2-bromopropanedioate Chemical compound CCOC(=O)C(Br)C(=O)OCC FNJVDWXUKLTFFL-UHFFFAOYSA-N 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 201000008525 senile cataract Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
Definitions
- the present invention relates to an organic dicarboxylic acid and a salt thereof, a process for the preparation thereof, and an activity against ocular oxidative damage of some typical compounds of the salt. Background technique
- Cataract is one of the most common blinding eye diseases, and blindness caused by cataracts accounts for about 40% of blind people around the world.
- cataracts With the advent of an aging society, the incidence of senile cataracts is increasing, so cataracts have been classified as common diseases and frequently-occurring diseases worldwide.
- the lens that has lost vision can be surgically removed and the adult lens is replaced, the surgical cost is expensive and there is a certain risk. Therefore, more patients need medication through the early stage of the disease to delay the development of lens opacity, avoid vision loss, delay surgery time or avoid surgery.
- the existing drug benzalysine has certain anti-cataract action, and as an aldose reductase inhibitor, it also has certain curative effect on polysaccharide cataract, but the drug is irritating to the eyes, and the related curative effect is still lacking. It is necessary to develop a new generation of drugs for the treatment of cataracts. Summary of the invention
- the present invention provides an organic dicarboxylic acid and a salt thereof and a process for the preparation thereof, which are useful as a medicament for treating cataract.
- the present invention designs and synthesizes 2-(1-benzyl (or substituted benzyl)-1H-indazole-3-oxy)malonic acid as an organic diacid with an alkali metal ion, ammonium ion or Amino acid action has been prepared to prepare a series of organic malonates with novel structures, in order to meet the low toxicity, low irritation, good water solubility and effective anti-ocular lens oxidation activity required for anti-cataract drugs. Human cataracts.
- the invention discloses a novel structure of a dicarboxylic acid and a salt thereof, and 2-(1-benzyl (or substituted benzyl)-1H-indazole-3-oxy)malonic acid as an organic dicarboxylic acid , the structure of such a compound is represented by formula (1),
- R is a hydrogen atom, a Cw alkyl group, a Cw alkoxy group or a halogen atom, and the compound represented by the formula (1) is abbreviated as H 2 L.
- M for monovalent cations such as Na +, K +, ⁇ 4 + and the like.
- organic diacid represented by the formula (1) forms a salt with an amino acid, it can be represented by the formula (3).
- A represents an amino acid such as lysine (including L-lysine, D-lysine, and a racemate composed of L-lysine and D-lysine), histidine (including L) Histidine, D-histidine and a racemate composed of L-histidine and D-form histidine).
- Another object of the present invention is to provide a process for producing an organic dicarboxylic acid represented by the formula (1), which is obtained by the reaction represented by the formula (4).
- X represents a Cl, Br or I atom
- R is as defined for R in the formula (1)
- R' is a C 1-4 alkyl group.
- the specific synthesis process is 1.0 part by mole of S1, and refluxed with 1.2 parts by mole of XCH(C0 2 R') 2 in the presence of 2.5 parts by mole of carbonic acid tetramethyl carbonate to obtain S2 in the solvent of ethylene glycol dimethyl ether.
- hydrolysis then refluxed in potassium hydroxide (or sodium hydroxide) solution, acidified to pH about 2 with dilute hydrochloric acid to give H 2 L.
- the organic diacid (H 2 L) represented by the formula (1) is reacted with a corresponding base such as sodium hydroxide, potassium hydroxide, aqueous ammonia or the like to obtain a salt (M 2 L) represented by the formula ( 2 );
- the structure of the compounds prepared according to the present invention has been confirmed by various analytical methods such as infrared light, shield nuclear magnetic resonance, organic shield or electrospray shield.
- the present invention provides an organic dicarboxylic acid and a salt thereof and a preparation method thereof, and discloses that some typical organic dicarboxylate compounds have an activity against ocular oxidative damage, and the compounds are less irritating to the eyes than the present There are therapeutic drugs, and the related effects are better.
- Example 1 The invention is further illustrated by the following examples, which are not intended to limit the invention.
- Example 1 The invention is further illustrated by the following examples, which are not intended to limit the invention.
- Example 2 The 2.0 mmol of the acid obtained in Example 2 was added to 5 mL of water, and the mixture was stirred for 5 min, and 4.0 mmol of a base or a 5 mL aqueous solution of 4.0 mmol of amino acid was added dropwise thereto, and the mixture was stirred at room temperature for 4 hr. Then, 20 mL of absolute ethanol was added to precipitate a solid, which was filtered, washed with 2 mL of anhydrous ethanol, and vacuum dried, and the obtained product was as follows:
- the rats and rabbits were sacrificed, and the eyeballs were removed by rinsing with 500 u/mL penicillin saline.
- the eyeballs and vitreous were removed from the posterior way, the suspensory ligament was removed, and the lens was removed.
- the penicillin containing 500 u/mL was used.
- anatomical microscopy was performed before the experiment to confirm that the lens had no turbidity and other abnormalities.
- Disinfected in a sterile culture medium (containing penicillin 100u/mL, streptomycin O.
- Negative control group DMEM medium containing no H 2 0 2 .
- Model group oxidative damage group: DMEM medium containing H 2 0 2 , FeCl 3 .
- Vitamin C In addition to the components of the model group, vitamin C was added (final concentration was lmmol/L).
- BDL Bendalysine
- Sample group In addition to the components of the model group, a sample was added (final concentration 0.5 mmol/L).
- the 12-well plate was lined with black and white backgrounds with different thicknesses and scored on a white background, and scored in three levels:
- Table 1 Percentage % of the results of the observation of the oxidative damage of the lens compound induced by the sample compound against 3 ⁇ 40 2 in rabbit eyes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
有机二羧酸和其盐及其制备方法 技术领域
本发明涉及有机二羧酸和其盐及其制备方法, 以及所述盐中一些典型化合物的 抗眼晶状体氧化损伤的活性。 背景技术
白内障是最常见的致盲眼病之一, 由白内障引起的失明占全世界盲人的 40%左 右。 随着人口老龄社会的到来, 老年性白内障的发病率日渐增长, 所以白内障已列 入世界性常见病和多发病。 虽然可以通过手术摘除已丧失视力的晶状体, 换置成人 工晶状体, 但手术价格學贵, 且存在一定的风险。 因此更多的患者在发病初期需要 通过药物治疗来延緩晶状体浑浊的发展, 避免视力的丧失, 推迟手术时间或避免手 术。 已有药物苄达赖氨酸具有一定的抗白内障作用, 且作为醛糖还原酶抑制剂对多 糖性白内障也有一定的疗效, 但该药对眼睛具有刺激性, 并且相关疗效还有所欠 缺, 因此研发新一代的治疗白内障的药物十分必要。 发明内容
发明目的: 本发明提供有机二羧酸和其盐及其制备方法, 该类化合物可作为治 疗白内障的药物。
技术方案: 本发明设计和合成了 2- ( 1-苄基(或取代苄基) -1H-吲唑 -3-氧基) 丙二酸, 其作为有机二酸与碱金属离子、 铵离子或氨基酸作用, 制备了一系列具有 新型结构的有机丙二酸盐, 目的在于使其满足抗白内障药物所需的低毒、 低刺激 性、 水溶性好及有效抗眼晶状体氧化的活性, 用于治疗人体白内障。 本发明披露了 一类具有新型结构的二羧酸及其盐, 以 2- ( 1-苄基(或取代苄基) -1H-吲唑 -3-氧 基) 丙二酸为有机二羧酸, 这类化合物的结构用式(1 )表示,
当式( 1 )所示有机二酸与阳离子 M形成盐时, 可由式(2)表示,
M2L 式(2)
其中, M代表一价阳离子, 如 Na+、 K+、 ΝΗ4+等。
当式(1)所示有机二酸与氨基酸形成盐时, 可由式(3)表示,
A2H2L 式( 3 )
其中, A代表氨基酸, 如赖氨酸(包括 L型赖氨酸、 D型赖氨酸及由 L型赖氨 酸和 D型赖氨酸组成的外消旋体) 、 组氨酸(包括 L型组氨酸、 D型组氨酸及由 L 型组氨酸和 D型组氨酸组成的外消旋体)等。
本发明的另一个目的是提供式 ( 1 ) 所示的有机二羧酸的制备方法, 通过式 (4)表示的反应得到,
其中, X代表 Cl、 Br或 I原子, R同式( 1 ) 中对 R的定义, R'为 C1-4烷基。 在此类有机二酸的合成中, 1-苄基(或取代苄基) -1H-吲唑 -3-醇(略为: S1)在碱 的存在下同 α-卤代丙二酸二酯反应, 得到 2- (1-苄基(或取代苄基) -1Η-吲唑 -3-氧 基) 丙二酸二酯 (略为: S2) , 然后, 该酯在碱性条件下水解, 经酸化后得到相应 的有机二酸( H2L ) 。
具体的合成工艺为 1.0摩尔份的 S1, 在 2.5摩尔份碳酸 4甲的存在下, 在乙二醇 二甲醚的溶剂中同 1.2摩尔份的 XCH(C02R')2回流反应得到 S2, 然后在氢氧化钾 (或氢氧化钠)溶液中回流水解, 用稀盐酸酸化到 pH约为 2, 得到 H2L。
将式 (1) 所示的有机二酸(H2L) 与相应的碱, 如氢氧化钠、 氢氧化钾、 氨水 等, 反应得到式 (2) 所示的盐 (M2L) ; 将式 (1) 所示的有机二酸与相应的氨基 酸, 如赖氨酸(包括 L型赖氨酸、 D型赖氨酸及由 L型赖氨酸和 D型赖氨酸组成的 外消旋体) 、 组氨酸(包括 L型组氨酸、 D型组氨酸及由 L型组氨酸和 D型组氨酸 组成的外消旋体)或其它氨基酸等, 反应得到式(3)所示的盐 (A2H2L) 。
本发明所制备的化合物的结构已被不同的分析方法诸如红外光语、 盾子核磁共 振光语、 有机盾谱或电喷雾盾谱确证。
有益效果: 本发明提供了一种有机二羧酸和其盐及其制备方法, 披露了一些典 型有机二羧酸盐化合物具有抗眼晶状体氧化损伤的活性, 该类化合物对眼睛的刺激 性小于现有治疗药物, 并且相关疗效较好。 具体实施方式
本发明由下述实施例得到进一步的说明, 但这些说明并不是限制本发明。 实施例 1.
2-(1-苄基 (或取代苄基) -1H-吲唑 -3-氧基)丙二酸酯的制备
在 250mL 三颈瓶中加入 12g(0.090mol) 3-羟基 -吲唑 (百灵威公司) , 3.94g
( 0.098mol ) 氢氧化钠, 90mL水, 40°C下搅拌 lOmin, 滴加 0.090mol苄氯(或取代 苄氯) , 在 70°C反应 2h, 有固体析出, 过滤, 滤饼用水洗涤, 得 1-苄基(或取代 苄基) -1H-吲唑 -3-醇。
在 lOOmL的四颈瓶中, 加入 40mL乙二醇二甲醚溶剂, 再加入 1-苄基(或取代 苄基) -1H-吲唑 -3-醇(10.5mmol)和 3.6g ( 26.1mmol ) 的碳酸钟混合。 所得混合液室 温下搅拌 lOmin, 滴加 3.0g ( 12.6mmol ) 的溴代丙二酸二乙酯 (百灵威公司) , 然 后加热回流 4h, 反应液由黄色变成红棕色,过滤。 将滤液浓缩, 柱层析 (展开剂: 石油醚 (60-90°C):乙酸乙酯 =1 : 1 ) , 可分别得到产物如下:
(1) 2-(1-苄基 -1H-吲唑 -3-氧基)丙二酸二乙酯 (S2-l)
收率: 39%
IR(KBr, cm-1) :2981 (m), 1768(s), 1748(s), 1619(m), 1235(s),744(m)
EI-MS: 382 [M+]
1HNMR(500MHz, CDCl3),5(ppm): 1.29-1.33(t, 6H, CH2C¾), 4.29~4.33(dd, 4H, C¾CH3),5.34(s, 2H, C¾C6H5), 5.77(s, 1H, CH(COOH)2), 7.08~7.83(m, 9H, 2Ar)
(2) 2-[l-(4-甲基-苄基) -1H-吲唑 -3-氧基]丙二酸二乙酯 (S2-2)
收率: 29%
IR(KBr, cm"1): 2985(w), 1764(s), 1743 (s), 1617(m), 1225(s),749(m)
EI-MS: 396 [M+]
1HNMR(500MHz, CDCl3),5(ppm): 1.28-1.31(t, 6H, CH2C¾), 2.40(s, 3H, CH2C6H4C¾), 4.29~4.33(dd, 4H, C¾CH3), 5.36(s, 2H, CH2C6H4CH3), 5.79(s, 1H, CH(COOH)2), 7.02~7.80(m, 8H, 2Ar)
(3) 2-[l-(3-氟-苄基) -1H-吲唑 -3-氧基]丙二酸二乙酯 (S2-3)
收率: 56%
IR(KBr, cm"1): 2983 (w), 1767(s), 1748(s), 1618(m), 1253 (s),745(m)
EI-MS: 400 [M+]
1HNMR(500MHz, CDCl3),5(ppm): 1.28-1.33(t, 6H, CH2C¾), 4.27~4.34(dd, 4H, C¾CH3),5.33(s, 2H, C¾C6H4F), 5.76(s, 1H, CH(COOH)2), 6.80~7.83(m, 8H, 2Ar)
(4) 2-[l-(3-氯-苄基) -1H-吲唑 -3-氧基]丙二酸二乙酯 (S2-4)
收率: 51%
IR(KBr, cm"1): 2984(m), 1735(s), 1619(w), 1247(s),747(m)
ESI-MS: 439 [M+Na] +
1HNMR(500MHz, CDCl3),5(ppm): 1.28-1.33(t, 6H, CH2C¾), 4.31~4.35(dd, 4H, C¾CH3),5.29(s, 2H, C¾C6H4C1), 5.76(s, 1H, CH(COOH)2), 7.02~7.83(m, 8H, 2Ar)
(5) 2-[l-(4-氯-苄基) -1H-吲唑 -3-氧基]丙二酸二乙酯 (S2-5)
收率: 18%
IR(KBr, cm"1): 2982(w), 1764(s), 1740(s), 1616(w), 1222(s),746(m)
ESI-MS: 439 [M+Na] +
1HNMR(500MHz, CDCl3),5(ppm): 1.27~1.34(t, 6H, CH2C¾), 4.28~4.32(dd, 4H, C¾CH3),5.29(s, 2H, C¾C6H4C1), 5.74(s, 1H, CH(COOH)2), 7.04~7.81(m, 8H, 2Ar) 实施例 2.
2-(l-苄基 (或取代苄基) -1H-吲唑 -3-氧基)丙二酸的制备
将实施例 1 所得酯 (2.7mmol)分别加入到含 0.3g氢氧化钾(5.4mmol ) 的 10mL 水溶液中, 加热回流 2h, 然后用 1M盐酸调节到 pH=2, 有白色固体析出, 过滤, 用少量水洗, 千燥得如下化合物:
(1) 2-(1-苄基 -1H-吲唑 -3-氧基)丙二酸(Η2Ι )
收率: 93%
mp: 182-186 V (分解)
IR(KBr, cm"1): 3033 (m),2934(m), 1741 (s), 1620(m), 1257(s), 746(m)、 711(m)
ESI-MS: 325 [M-H]—
1HNMR(500MHz, D20),5(ppm): 5.30(s, 2H, C¾C6H5), 5.36(s, 1H, CH(COOH)2), 7.00~7.73(m, 9H, 2Ar);
(2) 2-[l-(4-甲基-苄基) -1H-吲唑 -3-氧基]丙二酸(HzL2)
收率: 98%
mp: 144-146°C
IR(KBr, cm-1):3023(m),2920(m),1755(s), 1618(m), 1255(s), 744(s)、 727(m)
ESI-MS: 379 [M+K]+
1HNMR(500MHz, D20),5(ppm): 2.16(s, 3H, CH2C6H4C¾), 5.29(s, 2H, C¾C6H4CH3), 5.46(s, IH, CH(COOH)2), 6.97~7.75(m, 8H, 2Ar);
(3) 2-[l-(3-氟-苄基) -IH-吲唑 -3-氧基]丙二酸 (HzL3)
收率: 96%
mp: 138-140 °C
IR(KBr, cm-1):3065(m),2925(w), 1732(s), 1618(m), 1254(s),743 (s)
ESI-MS: 383 [M+K]+ 、 367 [M+Na]+、 345 [M+H]+
1HNMR(500MHz, D20),5(ppm): 5.41(s, 2H, CH2C6H4F), 5.49(s, IH, CH(COOH)2), 6.82~7.85(m, 8H, 2Ar);
(4) 2-[l-(3-氯-苄基) -IH-吲唑 -3-氧基]丙二酸(ItL4)
收率: 98%
mp: 137-139°C
IR(KBr, cm" ^ : 3063 (m),2940(m), 1749(s), 1619(m), 1247(s), 745(s)、 725(m)
ESI-MS: 399 [M+K]+、 361 [M+H]+
1HNMR(500MHz, D20),5(ppm): 5.40(s, 2H, CH C6H4C1), 5.5 l(s, IH, CH(COOH)2), 7.04~7.85(m, 8H, 2Ar);
(5) 2-[l-(4-氯-苄基) -IH-吲唑 -3-氧基]丙二酸(H2L5)
收率: 88%
mp: 1 14-1 16°C
ESI-MS: 399 [M+K] 361 [M+H]+
IR(KBr, cm"1) : 3064(m),2921 (m), 1747(s), 1619(m), 1251(s), 740(s)
1HNMR(500MHz, D20),5(ppm): 5.32(s, 2H, CH2C6H4C1), 5.46(s, IH, CH(COOH)2), 7.01~7.78(m, 8H, 2Ar) 实施例 3.
2-(l-苄基 (或取代苄基) -IH-吲唑 -3-氧基)丙二酸盐的制备
将实施例 2所得酸 2.0mmol分别加入到 5mL水中, 搅拌 5min, 滴加 4.0mmol 碱或 4.0mmol氨基酸的 5mL水溶液, 室温搅拌 4h, 减压浓缩除水, 得到油状物,
然后加入 20mL无水乙醇, 析出固体, 过滤, 用 2mL无水乙醇洗涤, 真空千燥, 所 得产物如下所示:
( 1 ) 2-(1-苄基 -1H-吲唑 -3-氧基)丙二酸'二钠盐 ( Y1 )
收率: 75%
IR(KBr, ^_1):2983 ( w ) , 1643(s), 1334(m),741(m),723(m)
1HNMR(500MHz, D20),5(ppm): 5.21(s, 1H, CH(COO )2), 5.33(s, 2H, Cff2C6H5), 7.03~7.79(m, 9H, 2Ar)
( 2 ) 2-(l-苄基 -1H-吲唑 -3-氧基)丙二酸'二钾盐 ( Y2 )
收率: 86%
IR(KBr, cm"1): 2978 ( w ) , 1639(s), 1328(m),740(m),721(m)
1HNMR(500MHz, D20),5(ppm): 5.23(s, 1H, CH(COO )2), 5.35(s, 2H, Cff2C6H5), 6.97~7.78(m, 9H, 2Ar)
( 3 ) 2-(l-苄基 -1H-吲唑 -3-氧基)丙二酸'二铵盐 ( Y3 )
收率: 75%
IR(KBr,。!^):3197 ( s ) , 1593(s), 1326(s), l 105(m),771(s),746(m)
1HNMR(500MHz, D20),5(ppm): 5.22(s, 1H, CH(COO )2), 5.34(s, 2H, Cff2C6H5), 7.03~7.81(m, 9H, 2Ar)
( 4 ) 2-(l-苄基 -1H-吲唑 -3-氧基)丙二酸 '二组氨酸盐 (Y4 )
收率: 92%
IR(KBr, cm"1):3128(m),3026(m), 1618(s), 1329(m), 1259(w),744(m)
1HNMR(500MHz, D20),5(ppm): 3.10~3.24(m, 4H, 2CH2 of Histidine), 3.89~3.94(m, 2H, 2CHNH2COOH of Histidine), 5.28(s, 1H, CH(COO")2), 5.34(s, 2H, C¾C6H5), 7.05~7.80(m, 1 1H, 9H of 2Ar, and 2H of 2 Imidazole), 8.27(s, 2H, 2H of 2 Imidazole)
( 5 ) 2-(l-苄基 -1H-吲唑 -3-氧基)丙二酸 ·二赖氨酸盐 ( Y5 )
收率: 86%
IR(KBr, cm"1) :3031 (s),2941 (s), 1615(s), 1325(m),741 (m)
1HNMR(500MHz, D20),5(ppm): 1.30~1.43(m, 4H, 2H2NC2H4C¾CH2 of Lysine), 1.60~1.63(m, 4H, 2H2NC2H4CH2C¾ of Lysine), 1.78~1.82(m, 4H, 2H2NCH2C¾C2H4 of Lysine), 2.90~2.93(m, 4H, 2H2NC¾CH2C2H4 of Lysine), 3.65(m, 2H, 2CH( H2)COOH of Lysine), 5.24(s, 1H, CH(COO")2), 5.36(s, 2H, CH,C6H5), 7.09 7.8 l(m, 9H, 2Ar)
( 6 ) 2-[l-(4-甲基-苄基) -IH-吲唑 -3-氧基]丙二酸 ·二钠盐 ( Y6 )
收率: 76%
IR(KBr, cm"1):2983(m), 1621(s), 1336(s), 1256(m),746(m)
1HNMR(500MHz, D20),5(ppm): 2.15(s,3H, C6H4C¾), 5.22(s, IH, CH(COO")2), 5.27(s, 2H, C¾C6H4CH3), 6.97~7.80(m, 8H, 2Ar)
( 7 ) 2-[l-(4-甲基-苄基) -IH-吲唑 -3-氧基]丙二酸 ·二钾盐 ( Y7 )
收率: 80%
IR(KBr, cm"1):2986(m), 1625(s), 1338(m), 1255(m),744(m)
1HNMR(500MHz, D20),5(ppm): 2.17(s,3H,C6H4CH3), 5.25(s, IH, CH(COO")2), 5.30(s, 2H, C¾C6H4CH3), 6.99~7.85(m, 8H, 2Ar)
( 8 ) 2-[l-(4-甲基-苄基) -IH-吲唑 -3-氧基]丙二酸 ·二铵盐 ( Y8 )
收率: 70%
IR(KBr, cm"1):3330(s),2983(m), 1600(s), 1331(m),746(m)
nHNMR(500MHz, D20),5(ppm): 2.13(s, 3H, C6H4C¾), 5.21(s, IH, CH(COO")2), 5.28(s, 2H, C¾C6H4CH3), 6.89~7.80(m, 8H, 2Ar)
( 9 ) 2-[l-(4-甲基-苄基) -IH-吲唑 -3-氧基]丙二酸 '二赖氨酸盐 ( Y9 )
收率: 88%
IR(KBr, cm"1):3432(s),2930(s), 1619(s), 1335(m),743(m)
1HNMR(500MHz, D20),5(ppm): 1.30-1.38 (m, 4H, 2H2NC2H4C¾CH2 of Lysine), 1.54~1.64(m, 4H, 2H2NC2H4CH2C¾ of Lysine), 1.74~1.81(m, 4H, 2H2NCH2C¾C2H4 of Lysine), 2.12(s, 3H, CH2C6H4C¾), 2.86~2.91(m, 4H, 2H2NC¾CH2C2H4 of Lysine), 3.61 ~ 3.65(m, 2H, 2CH( H2)COOH of Lysine), 5.20(s, 2H, C¾C6H5CH3), 5.28(s, IH, CH(COO")2), 6.92~7.76(m, 8H, 2Ar)
( 10 ) 2-[l-(3-氟-苄基) -IH-吲唑 -3-氧基]丙二酸 ·二钠盐 ( Y10 )
收率: 83%
IR(KBr, cm"1): 2927(w), 1619(s), 1337(m), 739(m)
1HNMR(500MHz, D20),5(ppm): 5.22(s, IH, CH(COOH)2), 5.34(s, 2H, C¾C6H4F), 6.77~7.80(m, 8H, 2Ar)
( 11 ) 2-[l-(3-氟-苄基) -IH-吲唑 -3-氧基]丙二酸 ·二钾盐 ( Y11 )
收率: 80%
IR(KBr, cm"1) :2929(w), 1605(s), 1331 (m), 741(m)
!HNMR OOMHz, D20),5(ppm): 5.22(s, 1H, CH(COOH)2), 5.30(s, 2H, C¾C6H4F), 6.75~7.80(m, 8H, 2Ar)
( 12 ) 2-[l-(3-氟-苄基) -1H-吲唑 -3-氧基]丙二酸 ·二铵盐 ( Yl2 )
收率: 75%
IR(KBr, cm"1): 3340 ( s ) ,2931(w), 1641(s), 1336(m), 743 (m)
1HNMR(500MHz, D20),5(ppm): 5.35(s, 1H, CH(COOH)2), 5.43(s, 2H, C¾C6H4F), 6.77~7.78(m, 8H, 2Ar)
( 13 ) 2-[l-(3-氟-苄基) -1H-吲唑 -3-氧基]丙二酸 ·二组氨酸盐 ( Y13 )
收率: 84%
IR(KBr, cm"1): 3154(s), 3012(m), 1600(s), 1331 (m), 1226(w), 741 (m)
1HNMR(500MHz, D20),5(ppm): 3.10~3.13(d, 4H, 2CH2 of Histidine), 3.83~3.87(m, 2H, 2CHNH2COOH of Histidine), 5.22(s, 1H, CH(COO")2), 5.26(s, 2H, C¾C6H4F), 6.71~7.73(m, 10H, 2Ar and 2H of 2 Imidazole of Histidine), 8.33(s, 2H, 2 Imidazole of Histidine)
( 14 ) 2-[l-(3-氟-苄基) -1H-吲唑 -3-氧基]丙二酸 ·二赖氨酸盐 ( Y14 )
收率: 85%
IR(KBr, cm"1): 3435(s),2931 (s), 1622(s), 1328(m),744(m)
1HNMR(500MHz, D20),5(ppm): 1.32~1.46(m, 4H, 2H2NC2H4C¾CH2 of Lysine), 1.55~1.66(m, 4H, 2H2NC2H4CH2C¾ of Lysine), 1.72~1.79(m, 4H, 2H2NCH2C¾C2H4 of Lysine), 2.89~2.93(m, 4H, 2H2NC¾CH2C2H4 of Lysine), 3.55~3.59(m, 2H, 2CH( H2)COOH of Lysine), 5.25(s, 1H, CH(COO")2), 5.35(s, 2H, C¾C6H4F), 6.80~7.87(m, 8H, 2Ar)
( 15 ) 2-[l-(3-氯-苄基) -1H-吲唑 -3-氧基]丙二酸 ·二钠盐 ( Y15 )
收率: 80%
IR(KBr, cm"1): 2937(w), 1619(s), 1336(s), 744(m)
1HNMR(500MHz, D20),5(ppm): 5.22(s, 1H, CH(COOH)2), 5.26(s, 2H, C¾C6H4C1), 6.94~7.80(m, 8H, 2Ar)
( 16 ) 2-[l-(3-氯-苄基) -1H-吲唑 -3-氧基]丙二酸 ·二钾盐 ( Y16 )
收率: 78%
IR(KBr, cm"1):2940(w), 1605(s), 1337(s),746(m)
!HNMR OOMHz, D20),5(ppm): 5.39(s, 1H, CH(COOH)2), 5.43(s, 2H, C¾C6H4C1), 7.08~7.95(m, 8H, 2Ar)
( 17 ) 2-[l-(3-氯-苄基) -1H-吲唑 -3-氧基]丙二酸 ·二铵盐 ( Y17 )
收率: 71%
IR(KBr, cm"1):3250(s),2942(m), 1641(s), 1322(m),746(m)
1HNMR(500MHz, D20),5(ppm): 5.23(s, 1H, CH(COOH)2), 5.33(s, 2H, C¾C6H4C1), 6.76~7.81(m, 8H, 2Ar)
( 18 ) 2-[l-(3-氯-苄基) -1H-吲唑 -3-氧基]丙二酸 ·二组氨酸盐 ( Y18 )
收率: 82%
IR(KBr, cm"1):3132(s),2932(m), 1640(s), 1326(m),742(m)
1HNMR(300MHz,D2O), 5(ppm): 3.10 (m, 4H, 2CH2 of Histidine), 3.81~3.83(m, 2H, 2CHNH2COOH of Histidine), 5.16(s, 1H, CH(COO")2), 5.22(s, 2H, C¾C6H4C1), 6.86~7.69(m, 10H, 8H of 2Ar and 2H of 2 Imidazole of Histidine), 8.32(s, 2H, 2 Imidazole of Histidine)
( 19 ) 2-[l-(3-氯-苄基) -1H-吲唑 -3-氧基]丙二酸 ·二赖氨酸盐 ( Y19 )
收率: 91%
IR(KBr, cm"1):2934(m2), 1613(s)„1320(m), 1105(m),741(m4)
1HNMR(500MHz, D20),5(ppm): 1.26~1.34(m, 4H, 2H2NC2H4C¾CH2 of Lysine), 1.49~1.56(m, 4H, 2H2NC2H4CH2C¾ of Lysine), 1.72~1.74(m, 4H, 2H2NCH2C¾C2H4 of Lysine), 2.81~2.86(m, 4H, 2H2NC¾CH2C2H4 of Lysine), 3.52~3.62(m, 2H, 2CH( H2)COOH of Lysine), 5.13(s, 2H, CH2C6H4C1), 5.21(s, 1H, CH(COO )2), 6.88~7.76(m, 8H, 2Ar)
( 20 ) 2-[l-(4-氯-苄基) -1H-吲唑 -3-氧基]丙二酸 ·二钠盐 ( Y20 )
收率: 84%
IR(KBr, cm"1): 2980(w), 1642(s), 1336(m), 739(m)
1HNMR(500MHz, D20),5(ppm): 5.16(s, 2H, C¾C6H4C1), 5.22(s, 1H, CH(COOH)2), 6.92~7.76(m, 8H, 2Ar)
( 21 ) 2-[l-(4-氯-苄基) -1H-吲唑 -3-氧基]丙二酸 ·二钾盐 ( Y21 )
收率: 82%
IR(KBr, cm"1): 2982(w), 1636(s), 1325(m),741(m)
!HNMR OOMHz, D20),5(ppm): 5.18(s, 1H, CH(COOH)2), 5.24(s, 2H, C¾C6H4C1), 6.99~7.83(m, 8H, 2Ar)
( 22 ) 2-[l-(4-氯-苄基) -1H-吲唑 -3-氧基]丙二酸 ·二铵盐 ( Y22 )
收率: 78%
IR(KBr,cm-1): 3232(s),2985(w), 1612(s), 1323(m),743(m)
1HNMR(500MHz,D2O),5(ppm): 5.24(s, 1H, CH(COOH)2), 5.31(s, 2H, C¾C6H4C1), 7.08~7.96(m, 8H, 2Ar)
( 23 ) 2-[l-(4-氯-苄基) -1H-吲唑 -3-氧基]丙二酸 ·二组氨酸盐 ( Y23 )
收率: 94%
IR(KBr, cm"1): 3162(m),2978(m), 1638(s), 1315(m),746(m)
1HNMR(500MHz, D20),5(ppm): 3.00-3.14 (m, 4H, 2CH2 of Histidine), 3.81~3.85(m, 2H, 2CHNH2COOH of Histidine), 5.19(s, 1H, CH(COO )2), 5.25(s, 2H, CH2C6H4C1), 6.93~7.71(m, 10H, 8H of 2Ar and 2H of 2 Imidazole of Histidine), 812(s, 2H, 2 Imidazole of Histidine)
( 24 ) 2-[l-(4-氯-苄基) -1H-吲唑 -3-氧基]丙二酸 ·二赖氨酸盐 ( Y24 )
收率: 93%
IR(KBr, cm-1) :2930(m), 1619(s), 1316(m), 1108(m),740(s)
1HNMR(500MHz, D20),5(ppm): 1.24~1.32(m, 4H, 2H2NC2H4C¾CH2 of Lysine), 1.48-1.58(m, 4H, 2H2NC2H4CH2C¾ of Lysine), 1.65~1.67(m, 4H, 2H2NCH2C¾C2H4 of Lysine), 2.80~2.85(m, 4H, 2H2NC¾CH2C2H4 of Lysine), 3.45-3.53(m, 2H, 2CH( H2)COOH of Lysine), 5.19(s, 1H, CH(COO )2), 5.21(s, 2H, CH2C6H4C1), 6.95~7.75(m, 8H, 2Ar) 典型化合物的活性
选择一些典型化合物进行了体外抗 ¾02致眼晶状体氧化损伤能力的研究。 具 体实验如下:
1. 眼睛晶状体培养
将大鼠、 家兔处死, 取出眼球用含 500u/mL青霉素生理盐水漂洗后, 仔细从后 路剖开眼球除去球壁盒和玻璃体, 剥离悬韧带, 取出晶状体, 用含 500u/mL青霉 素、 0.5mg/mL链霉素 PBS液漂洗 5min后, 实验前行解剖镜检查,确定晶状体无混浊 及其他异常后。 置于已装有 2mL DMEM/high glucose (北京赛默飞司尔生物化学制 品有限公司商品) 灭菌培养液(含青霉素 100u/mL、 链霉素 O. lmg/mL ) 的消毒 12
孔板中, 分别加入不同待筛选化合物在温度 37 °C , 湿度 95%, 5%C02培养箱中预 培养 lh后, 再在各孔中加入 2mL含 H202及 FeCl3 (每孔总浓度家兔的 H202为 2%, 大鼠的 H202为 0.5%, FeCl3均为 0.02% ) 的 DEME培养液, 每孔共含 4mL培 养液, 在同等条件下培养 24h。 试验分为下述几组, 分批试验, 每批设阴性对照组 和模型组。
A.阴性对照组: 不含 H202的 DMEM培养液。
B.模型组 (氧化损伤组): 含 H202、 FeCl3的 DMEM培养液。
C.维生素 C组: 除模型组各成分外, 另加维生素 C (最终浓度为 lmmol/L ) 。
D.苄达赖氨酸 (BDL)组 (BDL 由浙江莎普爱思药业股份有限公司提供, 纯度
>98.5% ) : 除模型组各成分外, 另加 BDL (最终浓度 0.5mmol/L ) 。
E.样品组: 除模型组各成分外, 另加入样品 (最终浓度 0.5mmol/L ) 。
2. 形态学观察
培养 24h后, 观察眼睛晶状体混浊情况, 在 12孔板下衬以白色底画有不同粗细 的黑色 +状背景拍照并计分, 分为 3个级别:
-为正常透明晶体;
+为轻度混浊 (, 1号 +字略有模糊,但是可见, 2号 +字清晰可见); I度
+ +为中度混浊 (2号 +字略有模糊但是可见 ,3号 +字清晰可见); II度
+ + +为整个晶体混浊, 3号 +字不能清晰可见); III度
3. 结果
样品化合物抗 H202致体外家兔眼晶状体氧化损伤能力的研究结果见表 1 ; 样品 化合物抗 ¾02致体外大鼠眼晶状体氧化损伤能力的研究结果见表 2。
根据表 1,对 H202致体外家兔眼晶状体氧化损伤有抑制作用的化合物为 Y4和 Y10, 对 ¾02致体外家兔眼晶状体损伤抑制作用不明显为 Yl、 Υ2、 Υ5和 Υ19。
根据表 2,对 Η202致体外大鼠眼晶状体氧化损伤有抑制作用的化合物为 Yl、 Y4、 Y5、 Y14和 Y19, 对 Η202致体外大鼠眼晶状体氧化损伤抑制作用不明显为 Υ2 和 Υ10。
表 1 : 样品化合物抗 ¾02致体外家兔眼晶状体氧化损伤能力 观察结果 各度百分率% 评价
― + ++ +++ 总数 + >++
( I )度 (IIJID度
A繊讎 I) 61 61 100
B (模型组) 26 31 22 79 33 67
C (VC组) 13 16 2 31 42 58
D (BDL组) 9 3 12 75 25 V
Yl 4 3 7 57 43
Y2 2 3 2 7 29 71
Y4 14 7 21 67 33 V
Y5 2 2 2 6 33 67
Y10 4 1 5 80 20 V
Y19 3 3 100 评价标准: 根据模型组大量试验, 将各组产生晶状体混浊各度的百分率和模型组产 生晶状体混浊各度的百分率比作为定义。 其中, 轻度好转 ( : ++ (即 Π ΠΙ度) 的百分 率%应<67%, +( 1度) 的百分率%应>33%; 中度好转 (ΛΝ):++(Π ΠΙ度)的百分率%进 一步降低; 并出现 0(-)的百分率%; 明显好转 (W ):++(niii度)及 +( 1度)的百分率% 消失, 晶状体基本透明。 表 2: 样品化合物抗 Η202致体外大鼠眼晶状体氧化损伤能力
Claims
中回流
X代表 Cl、 Br或 I原子, R为氢原子、 C1-3烷基、 C1-3烷氧基或卤原子, R'为
Ci-4 基。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10829544.5A EP2502916B1 (en) | 2009-11-16 | 2010-11-12 | Organic dicarboxylic acids, salts and preparation method thereof |
US13/509,985 US8637677B2 (en) | 2009-11-16 | 2010-11-12 | Organic dicarboxylic acids, salts and preparation method thereof |
JP2012538181A JP5763664B2 (ja) | 2009-11-16 | 2010-11-12 | 有機ジカルボン酸、その塩およびそれらの調製方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102126925A CN101704785B (zh) | 2009-11-16 | 2009-11-16 | 有机二羧酸和其盐及其制备方法 |
CN200910212692.5 | 2009-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011057580A1 true WO2011057580A1 (zh) | 2011-05-19 |
Family
ID=42375049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2010/078691 WO2011057580A1 (zh) | 2009-11-16 | 2010-11-12 | 有机二羧酸和其盐及其制备方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8637677B2 (zh) |
EP (1) | EP2502916B1 (zh) |
JP (1) | JP5763664B2 (zh) |
CN (1) | CN101704785B (zh) |
WO (1) | WO2011057580A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101704785B (zh) | 2009-11-16 | 2012-02-29 | 东南大学 | 有机二羧酸和其盐及其制备方法 |
CN102206185B (zh) * | 2011-04-15 | 2014-04-02 | 吉林大学 | 一种苄达赖氨酸及其类似物的精制工艺 |
CN103641784B (zh) * | 2013-12-03 | 2018-06-19 | 杭州民生药业有限公司 | 一种苄达赖氨酸合成工艺 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101703503A (zh) * | 2009-11-16 | 2010-05-12 | 南京医科大学 | 有机二羧酸盐在防治白内障药物中的应用 |
CN101704785A (zh) * | 2009-11-16 | 2010-05-12 | 东南大学 | 有机二羧酸和其盐及其制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0191520B1 (en) * | 1985-02-12 | 1989-06-21 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | (1-phenylmethyl-5-hydroxy-1h-indazol-3-yl)-oxyacetic acid and salts thereof for use as a medicament, and pharmaceutical compositions containing them |
IT1221056B (it) * | 1985-02-12 | 1990-06-21 | Acraf | Sul trattamento della cataratta |
US5212159A (en) * | 1991-02-27 | 1993-05-18 | Senju Pharmaceutical Co., Ltd. | Anticataract composition |
TW207498B (zh) * | 1991-02-27 | 1993-06-11 | Senju Pharma Co | |
KR20030065304A (ko) * | 2000-03-17 | 2003-08-06 | 알콘, 인코퍼레이티드 | 녹내장 치료용 6-하이드록시-인다졸 유도체 |
CN1321640C (zh) * | 2005-09-08 | 2007-06-20 | 南京医科大学 | 苄达赖氨酸在制备治疗糖尿病周围神经病变药物中的应用 |
KR20090025367A (ko) * | 2006-06-28 | 2009-03-10 | 가부시키가이샤산와카가쿠켄큐쇼 | 신규 6-5계 이환식 복소환 유도체 및 그 의약용도 |
CN100569218C (zh) * | 2006-12-14 | 2009-12-16 | 宁夏康亚药业有限公司 | 苄达赖氨酸滴眼液及其制备方法 |
-
2009
- 2009-11-16 CN CN2009102126925A patent/CN101704785B/zh active Active
-
2010
- 2010-11-12 US US13/509,985 patent/US8637677B2/en active Active
- 2010-11-12 JP JP2012538181A patent/JP5763664B2/ja active Active
- 2010-11-12 EP EP10829544.5A patent/EP2502916B1/en active Active
- 2010-11-12 WO PCT/CN2010/078691 patent/WO2011057580A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101703503A (zh) * | 2009-11-16 | 2010-05-12 | 南京医科大学 | 有机二羧酸盐在防治白内障药物中的应用 |
CN101704785A (zh) * | 2009-11-16 | 2010-05-12 | 东南大学 | 有机二羧酸和其盐及其制备方法 |
Non-Patent Citations (1)
Title |
---|
LI YANGYAN ET AL.: "Synthesis of Bendazac lysine", CHEMICAL INDUSTRY TIMES, vol. 20, no. 4, 4 April 2006 (2006-04-04), pages 38 - 39, XP008157553 * |
Also Published As
Publication number | Publication date |
---|---|
JP5763664B2 (ja) | 2015-08-12 |
CN101704785A (zh) | 2010-05-12 |
US20120226051A1 (en) | 2012-09-06 |
US8637677B2 (en) | 2014-01-28 |
EP2502916A1 (en) | 2012-09-26 |
EP2502916B1 (en) | 2014-04-30 |
CN101704785B (zh) | 2012-02-29 |
JP2013510802A (ja) | 2013-03-28 |
EP2502916A4 (en) | 2013-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017248253B2 (en) | Silicone atoms containing ivacaftor analogues | |
ES2295128T3 (es) | Derivados de bencimidazol como inhibidores de quimasa humana. | |
JP6913698B2 (ja) | ウリジン二リン酸誘導体、プロドラッグ、組成物およびそれらの使用 | |
CA3078230A1 (en) | Compounds, compositions and methods for increasing cftr activity | |
CA3041675A1 (en) | N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis | |
CA3041676A1 (en) | Pyridazine derivatives, compositions and methods for modulating cftr | |
WO2018081378A1 (en) | Compounds, compositions, and methods for modulating cftr | |
FR2903986A1 (fr) | Nouveaux derives chromenes ou thiochromenes carboxamides, leur procede de preparation et leurs applications en therapeutique | |
JP7068743B2 (ja) | Mgat2阻害活性を有する縮合環誘導体を含有する医薬組成物 | |
WO2011057580A1 (zh) | 有机二羧酸和其盐及其制备方法 | |
WO1999061403A1 (fr) | Nouveaux derives vinylbenzene | |
WO2021213518A1 (zh) | 用于预防或治疗脂质代谢相关疾病的化合物 | |
JPS58154538A (ja) | アルキルアミノアルコ−ル誘導体、その製造法、並びに該誘導体を有効成分とする新規薬剤 | |
US6265437B1 (en) | Aminoalkanesulphonic acid derivatives, their preparation and their use as medicaments | |
CA2726666A1 (fr) | Derives de 2-oxo-alkyl-1-piperazin-2-one, leur preparation et leur application en therapeutique | |
JPS5841862A (ja) | 複素環式酢酸化合物および骨疾患の治療用組成物 | |
JP7262141B2 (ja) | シャペロン介在性オートファジー調節剤として有用な化合物 | |
SU1382401A3 (ru) | Способ получени тетрагидро-бета-карболиновых производных или их фармацевтически приемлемых солей | |
TW444012B (en) | Chromene derivatives and salts thereof, and pharmaceuticals containing the same | |
JPH0347165A (ja) | ピロールカルボン酸誘導体 | |
KR20080022940A (ko) | 의약용 트리에틸렌테트라민 이염산염의 제조방법 | |
TW201404772A (zh) | 噁唑烷酮類衍生物、其製備方法及其在醫藥上的應用 | |
JP2000191528A (ja) | ビタミンe誘導体を含有してなる抗炎症剤または抗アレルギ―剤 | |
US4820837A (en) | 1-hydroxy-oxo-5H-pyrido(3,2-a)phenoxazine-3-carboxylic acid esters | |
WO2024001115A1 (zh) | 一种贝壳衫烷型四环二萜类衍生物、其制备方法及医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10829544 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012538181 Country of ref document: JP Ref document number: 13509985 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010829544 Country of ref document: EP |